Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Porfimer sodium - Pinnacle Biologics

Drug Profile

Porfimer sodium - Pinnacle Biologics

Alternative Names: CL 184116; Photobarr; Photofrin; Photofrin II; Photofrin PDT; Photofrin Photodynamic Therapy - Axcan Pharma

Latest Information Update: 24 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator QLT
  • Developer Adare Pharmaceuticals; Novelion Therapeutics; Pinnacle Biologics; Roswell Park Cancer Institute; University of Pennsylvania
  • Class Antineoplastics; Hematoporphyrins
  • Mechanism of Action Photosensitisers; Reactive oxygen species stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - High-grade oesophageal dysplasia; Cholangiocarcinoma; Malignant-mesothelioma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Bladder cancer; Cervical cancer; Cervical dysplasia; Gastric cancer; High-grade oesophageal dysplasia; Non-small cell lung cancer; Oesophageal cancer
  • Phase II Malignant-mesothelioma
  • No development reported Brain cancer; Pancreatic cancer
  • Discontinued Cholangiocarcinoma; Glioblastoma

Most Recent Events

  • 12 Apr 2021 Discontinued - Phase-III for Cholangiocarcinoma (Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA, Switzerland, South Korea, Canada, Germany (IV)
  • 09 Apr 2021 Discontinued - Phase-II for Glioblastoma (Second-line therapy or greater) in USA (IV)
  • 22 Mar 2019 Concordia Laboratories completes a phase I trial for Non-small cell lung cancer in USA (NCT03344861)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top